Key Insights

Highlights

Success Rate

64% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

21.1%

4 terminated out of 19 trials

Success Rate

63.6%

-22.9% vs benchmark

Late-Stage Pipeline

5%

1 trials in Phase 3/4

Results Transparency

143%

10 of 7 completed with results

Key Signals

10 with results64% success

Data Visualizations

Phase Distribution

19Total
P 1 (9)
P 2 (9)
P 3 (1)

Trial Status

Completed7
Active Not Recruiting6
Terminated4
Recruiting2

Trial Success Rate

63.6%

Benchmark: 86.5%

Based on 7 completed trials

Clinical Trials (19)

Showing 19 of 19 trials
NCT03191149Phase 2Recruiting

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

NCT02498613Phase 2Active Not Recruiting

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

NCT00334815Phase 2Active Not Recruiting

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT01507428Phase 2Completed

Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer

NCT01386385Phase 1Active Not Recruiting

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT02503722Phase 1Active Not Recruiting

Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer

NCT01629498Phase 1Active Not Recruiting

Image-Guided, Intensity-Modulated Photon or Proton Beam Radiation Therapy in Treating Patients With Stage II-IIIB Non-small Cell Lung Cancer

NCT04892953Phase 2Recruiting

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

NCT02321501Phase 1Active Not Recruiting

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

NCT01413750Phase 2Terminated

Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer

NCT02520778Phase 1Completed

Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

NCT02773238Phase 2Completed

FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging

NCT00254384Phase 1Completed

Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery

NCT01912625Phase 1Terminated

Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT02706392Phase 1Terminated

Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies

NCT02535325Phase 1Completed

Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer

NCT02452463Phase 2Terminated

Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy

NCT00126581Phase 2Completed

Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer

NCT00693992Phase 3CompletedPrimary

Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy

Showing all 19 trials

Research Network

Activity Timeline